全文获取类型
收费全文 | 785479篇 |
免费 | 50460篇 |
国内免费 | 1030篇 |
专业分类
耳鼻咽喉 | 11055篇 |
儿科学 | 26968篇 |
妇产科学 | 23252篇 |
基础医学 | 123865篇 |
口腔科学 | 21892篇 |
临床医学 | 66145篇 |
内科学 | 145508篇 |
皮肤病学 | 18227篇 |
神经病学 | 55989篇 |
特种医学 | 29305篇 |
外国民族医学 | 105篇 |
外科学 | 120949篇 |
综合类 | 15702篇 |
现状与发展 | 1篇 |
一般理论 | 267篇 |
预防医学 | 57108篇 |
眼科学 | 18714篇 |
药学 | 59160篇 |
中国医学 | 1754篇 |
肿瘤学 | 41003篇 |
出版年
2018年 | 8418篇 |
2017年 | 6213篇 |
2016年 | 7041篇 |
2015年 | 7845篇 |
2014年 | 10496篇 |
2013年 | 16492篇 |
2012年 | 21456篇 |
2011年 | 23214篇 |
2010年 | 14132篇 |
2009年 | 12949篇 |
2008年 | 21883篇 |
2007年 | 23739篇 |
2006年 | 23826篇 |
2005年 | 22938篇 |
2004年 | 22313篇 |
2003年 | 21161篇 |
2002年 | 20631篇 |
2001年 | 35846篇 |
2000年 | 37247篇 |
1999年 | 30755篇 |
1998年 | 8166篇 |
1997年 | 7254篇 |
1996年 | 7398篇 |
1995年 | 6897篇 |
1994年 | 6453篇 |
1992年 | 23113篇 |
1991年 | 23696篇 |
1990年 | 23667篇 |
1989年 | 22869篇 |
1988年 | 21040篇 |
1987年 | 20645篇 |
1986年 | 19543篇 |
1985年 | 18746篇 |
1984年 | 13861篇 |
1983年 | 11887篇 |
1982年 | 6793篇 |
1979年 | 13428篇 |
1978年 | 9773篇 |
1977年 | 8256篇 |
1976年 | 7858篇 |
1975年 | 8936篇 |
1974年 | 10685篇 |
1973年 | 10188篇 |
1972年 | 9780篇 |
1971年 | 9367篇 |
1970年 | 8764篇 |
1969年 | 8274篇 |
1968年 | 7869篇 |
1967年 | 7190篇 |
1966年 | 6527篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
R. Di Raimondo J. Sanz-Esporrn R. Pl I. Sanz-Martn F. Luengo F. Vignoletti J. Nuez Mariano Sanz 《Clinical oral investigations》2020,24(7):2351-2361
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou 相似文献
43.
44.
45.
46.
47.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
48.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study 下载免费PDF全文
49.
E. M. Peterman C. Sullivan M. F. Goody I. Rodriguez-Nunez J. A. Yoder C. H. Kim 《Infection and immunity》2015,83(1):430-440
Mitochondria are known primarily as the location of the electron transport chain and energy production in cells. More recently, mitochondria have been shown to be signaling centers for apoptosis and inflammation. Reactive oxygen species (ROS) generated as by-products of the electron transport chain within mitochondria significantly impact cellular signaling pathways. Because of the toxic nature of ROS, mitochondria possess an antioxidant enzyme, superoxide dismutase 2 (SOD2), to neutralize ROS. If mitochondrial antioxidant enzymes are overwhelmed during severe infections, mitochondrial dysfunction can occur and lead to multiorgan failure or death. Pseudomonas aeruginosa is an opportunistic pathogen that can infect immunocompromised patients. Infochemicals and exotoxins associated with P. aeruginosa are capable of causing mitochondrial dysfunction. In this work, we describe the roles of SOD2 and mitochondrial ROS regulation in the zebrafish innate immune response to P. aeruginosa infection. sod2 is upregulated in mammalian macrophages and neutrophils in response to lipopolysaccharide in vitro, and sod2 knockdown in zebrafish results in an increased bacterial burden. Further investigation revealed that phagocyte numbers are compromised in Sod2-deficient zebrafish. Addition of the mitochondrion-targeted ROS-scavenging chemical MitoTEMPO rescues neutrophil numbers and reduces the bacterial burden in Sod2-deficient zebrafish. Our work highlights the importance of mitochondrial ROS regulation by SOD2 in the context of innate immunity and supports the use of mitochondrion-targeted ROS scavengers as potential adjuvant therapies during severe infections. 相似文献
50.